Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity

J Med Genet. 2024 Apr 8:jmg-2024-109876. doi: 10.1136/jmg-2024-109876. Online ahead of print.

¹ Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA dwarnock@uab.edu.
² Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

No abstract available

Keywords: Fabry Disease.